BackProtagonist Therapeutics Overview

Protagonist Therapeutics Current Assets

Protagonist Therapeutics's current assets is $810M.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$807.15M
33.96% YoYΔ $204.62M vs prior year quarter

Peer trimmed avg / median

Loading

Protagonist Therapeutics Current Assets History

Loading

Protagonist Therapeutics vs. peers: Current Assets Comparison

Loading

Protagonist Therapeutics Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Protagonist Therapeutics (PTGX) FAQ

The latest current assets for PTGX is $810M as of June 2026. That compares with $600M in the prior-year period — up 34.0% year over year. Investors often review this figure alongside Protagonist Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, PTGX's current assets moved from $600M to $810M — a 34.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Protagonist Therapeutics's operating scale or balance-sheet position.

A current assets figure of $810M for PTGX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting PTGX's current assets ($810M), review year-over-year change from $600M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Protagonist Therapeutics's current assets against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.